Skip to main content

Advertisement

SpringerLink
Log in

Treatment of chronic hepatitis B: New antiviral therapies

  • Published:
Current Gastroenterology Reports Aims and scope Submit manuscript

Abstract

Chronic hepatitis B infection is the most important cause of cirrhosis and hepatocellular carcinoma worldwide. Interferon-alpha has been shown to be effective in approximately one third of patients, and response seems to be sustained in long-term follow-up studies in Western countries. New treatments using lamivudine and other nucleoside analogues such as famciclovir, lobucavir, and adfovir showed promising results although sustained suppression of viral replication is unusual after discontinuation of therapy. The results of recent clinical studies using these nucleoside analogues are discussed in detail in this review. Other important issues such as drug resistance and the role of combination therapy are also addressed.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Alter MJ, Mast EE: The epidemiology of viral hepatitis in the United States. Gastroenterol Clin North Am 1994, 23:437 455.

    PubMed  Google Scholar 

  2. Maynard JE: Hepatitis B: global importance and need for control. Vaccine 1990, 8(suppl):518–520.

    Article  Google Scholar 

  3. Beasley RP, Hwang LY, Lin CC, et al.: Hepatocellular carcinoma and hepatitis B virus: a prospective study of 22707 men in Taiwan. Lancet 1981, ii:1128–1133.

    Google Scholar 

  4. Lee WM: Hepatitis B infection. N Engl J Med 1997, 337:1733–1745.

    Article  PubMed  CAS  Google Scholar 

  5. Wong VC, Ip HM, Reesink HW, et al.: Prevention of the HBsAg carrier state in newborn infants of mothers who are chronic carriers of HBsAg and HBeAg by administration of hepatitis-B vaccine and hepatitis-B immunoglobulin. Lancet 1984, i:921–926.

    Article  Google Scholar 

  6. Lo KJ, Tsai YT, Lee SD, et al.: Immunoprophylaxis of infection with hepatitis B virus in infants born to hepatitis B surface antigen-positive carrier mothers. J Infect Dis 1985, 152:817–822.

    PubMed  CAS  Google Scholar 

  7. Beasley RP, Hwung LY, Lee GC, et al.: Prevention of perinatally transmitted hepatitis B virus infections with hepatitis B immune globulin and hepatitis B vaccine. Lancet 1983, ii:1099–1102.

    Article  Google Scholar 

  8. Alberti A, Pontisso P, Fattovich G, et al.: Changes in serum hepatitis B virus (HBV) DNA positivity in chronic HBV infection: results of a long-term follow-up study of 138 patients. J Infect Dis 1986, 154:562–569.

    PubMed  CAS  Google Scholar 

  9. Fattovich G, Brollo L, Giustina G, et al.: Natural history and prognostic factors for chronic hepatitis type B Gut 1991, 32:284–288.

    Google Scholar 

  10. Liaw YF, Tai BI, Chu CM, et al.: The development of cirrhosis in patients with chronic type B hepatitis: a prospective study. Hepatology 1988, 8:493–496.

    Article  PubMed  CAS  Google Scholar 

  11. Weissberg JI, Andres LL, Smith CI, et al.: Survival in chronic hepatitis B: an analysis of 379 patients. Ann Intern Med 1984, 101:613–616.

    PubMed  CAS  Google Scholar 

  12. Ladenheim J, Yao F, Martin MC, et al.: Survival in chronic hepatitis B: a 15-year follow-up [abstract]. Hepatology 1993, 18:119A.

    Google Scholar 

  13. Garcia G, Smith CI, Weissberg JI, et al.: Adenine arabinoside monophosphate (vidarabine phosphate) in combination with human leukocyte interferon: the treatment of chronic hepatitis B. Ann Intern Med 1987, 107:278–285.

    PubMed  CAS  Google Scholar 

  14. Hoofnagle JH: Antiviral treatment of chronic type B hepatitis Ann Intern Med 1987, 107:414–415.

    PubMed  CAS  Google Scholar 

  15. Perrillo RP, Schoff ER, Davis GL, et al.: Randomized, controlled trial of interferon alfa-2b alone and after prednisone withdrawal for the treatment of chronic hepatitis B N Engl J Med 1990, 323:295–301.

    Article  PubMed  CAS  Google Scholar 

  16. Hoofnagle JH, Peters M, Mullen KD, et al.: Randomized, controlled trial of recombinant human a-interferon in patients with chronic hepatitis B. Gastroenterology 1988, 95:1318–1325.

    PubMed  CAS  Google Scholar 

  17. Müller R, Baumgarten R, Markus R, et al.: Treatment of chronic hepatitis B with interferon alfa-2b. J Hepatol 1990, 11(suppl 1):S137–140.

    Article  PubMed  Google Scholar 

  18. Waked I, Amin M, Abdel Fattah S, et al.: Experience with interferon in chronic hepatitis-B in Egypt. . J Chemother 1990, 2:310–318.

    PubMed  CAS  Google Scholar 

  19. Lok AS, Wu PC, Lai CL, et al.: A controlled trial of interferon with or without prednisone priming for chronic hepatitis B. Gastroenterology 1992, 8:125–137.

    Google Scholar 

  20. Wong DLH, Cheung AM, O‘Rourke KO, et al.: Effect of alphainterferon treatment in patients with hepatitis B e-antigenpositive chronic hepatitis B: a meta-analysis. Ann Intern Med 1993, 119:312–323.

    PubMed  CAS  Google Scholar 

  21. Perrillo R, Tamburro C, Regenstein F, et al.: Low dose, titratable interferon alfa in decompensated liver disease caused by chronic infection with hepatitis B virus. Gastroenterology 1995, 109:908–916

    Article  PubMed  CAS  Google Scholar 

  22. Hoofnagle JH, di Bisceglie AM, Waggoner JG, et al.: Interferon alfa for patients with clinically apparent cirrhosis due to chronic hepatitis B. Gastroenterology 1993, 104:1116–1121.

    PubMed  CAS  Google Scholar 

  23. Perrillo RP: Factors influencing response to interferon in hepatitis B. implications for Asian and Western populations Hepatology 1990, 12:1433–1434.

    Article  PubMed  CAS  Google Scholar 

  24. Korenman J, Baker B, Waggoner J, et al.: Long-term remission of chronic hepatitis B after alpha-interferon therapy. Ann Intern Med 1991, 114:629–634.

    PubMed  CAS  Google Scholar 

  25. Lau DTY, Everhart J, Kleiner DE, et al.: Long-term follow-up o patients with chronic hepatitis B treated with interferon alfa. Gastroenterology 1997, 113:1660–1667.

    Article  PubMed  CAS  Google Scholar 

  26. Carreno V, Castillo I, Molina J, et al.: Long-term follow-up of hepatitis B chronic carriers who responded to interferon therapy. Ann Intern Med 1991, 114:629–634.

    Google Scholar 

  27. Niederau C, Heintges T, Lange S, et al.: Long-term follow-up of HBeAg-positive patients treated with interferon alfa for chronic hepatitis B. N Engl J Med 1996, 334:1422–1427.

    Article  PubMed  CAS  Google Scholar 

  28. Lok ASF, Chung HT, Liu VWS, et al.: Long-term follow-up of chronic hepatitis B patients treated with interferon alfa. Gastroenterology 1993, 105:1833–1838.

    PubMed  CAS  Google Scholar 

  29. Mutchnick MG, Lindsay KL, Schiff ER, et al.: Thymosin a1 treatment of chronic hepatitis B: a multicenter randomized placebo-controlled double blind study [abstract]. Gastroenterology 1995, 108:A1127.

    Google Scholar 

  30. Chien RN, Liaw YF, Chen TC, et al.: Efficacy of thymosin a 1 in patients with chronic hepatitis B: a randomized, controlled trial. Hepatology 1998, 27:1383–1387.

    Article  PubMed  CAS  Google Scholar 

  31. Hoofnagle JH, Lau D. New therapies for chronic hepatitis B. J Viral Hepatol 1997, 4 suppl 1:41–50.

    Google Scholar 

  32. McKenzie R, Fried MW, Sallie R, et al.: Hepatic failure and lactic acidosis due to fialuridine (FIAU), an investigational nucleoside analogue for chronic hepatitis B. N Engl J Med 1995, 333:1099–1105.

    Article  PubMed  CAS  Google Scholar 

  33. Swartz MN: Mitochondrial toxicity: new adverse drug effects. N Engl J Med 1995, 333:1146–1148.

    Article  PubMed  CAS  Google Scholar 

  34. Eron JJ, Benoit SC, Jemsek J, et al.: Treatment with lamivudine, zidovudine or both in HIV positive patients with 200 to 500 CD4 + cells per cubic millimeter. N Engl J Med 1995, 333:1662–1669.

    Article  PubMed  CAS  Google Scholar 

  35. Benhamou Y, Katlama CH, Lunel F, et al.: Effects of lamivudine on replication of hepatitis B virus in infected men. Ann Intern Med 1996, 129:1705–1712.

    Google Scholar 

  36. Tyrrell DLJ, Fischer K, Sarani K, et al.: Treatment of chimpanzees and ducks with lamivudine 2′3′ dideoxy 3′ thiacytidine results in a rapid suppression of hepadnaviral DNA in sera [abstract]. Clin Invest Med 1993, 16 (suppl 4):B 77.

    Google Scholar 

  37. Doong SL, Tsai CH, Schinazi RF, et al.: Inhibition of the replication of hepatitis B in vitro by 2′3′-dideoxy-3′ thiacytidine and related analogues Proc Natl Acad Sci U S A 1991, 88:8495–8499.

    Article  PubMed  CAS  Google Scholar 

  38. Severini A, Liu XY, Wilson JS, et al.: Mechanism of inhibition of duck hepatitis B virus polymerase by 2′, 3′-dideoxy-3′ -thiacytidine. Antimicrob Agents Chemother 1995, 39:1430–1435.

    PubMed  CAS  Google Scholar 

  39. Dienstag JL, Perill RP, Schiff ER, et al.: A preliminary trial of lamivudine for chronic hepatitis B infection. N Engl J Med 1995, 333:1657–1661.

    Article  PubMed  CAS  Google Scholar 

  40. Lai CL, Ching CK, Tung ANM, et al.: Lamivudine is effective in suppressing hepatitis B virus DNA in Chinese hepatitis B surface antigen carriers: a placebo-controlled trial. Hepatology 1997, 25:241–244.

    Article  PubMed  CAS  Google Scholar 

  41. Nevens F, Main J, Hankoop P, et al.: Lamivudine therapy for chronic hepatitis B: a six-month randomized dose-ranging study. Gastroenterology 1997, 113:1258–1263.

    Article  PubMed  CAS  Google Scholar 

  42. Lai CL, Chien RN, Leung NWY, et al.: A one-year trial of lamivudine for chronic hepatitis B N Engl J Med 1998, 339:61–68.

    Article  PubMed  CAS  Google Scholar 

  43. Dienstag J, Schiff E, Wright T, et al.: Lamivudine treatment for 1 year in previously untreated US hepatitis B patients: histologic improvement and hepatitis B E-Antigen (HBeAg) seroconversion [abstract]. Dig Dis Week 1998, 1:A 1.

    Google Scholar 

  44. Knodell RG, Ishak KE, Black WC, et al.: Formulation and application of a numerical scoring system for assessing histological activity in asymptomatic chronic active hepatitis Hepatology 1981, 1:431–435.

    Article  PubMed  CAS  Google Scholar 

  45. Liaw YF, Lai CL, Leung NWY, et al.: Two-year lamivudine therapy in chronic hepatitis B infection: results of a placebo controlled multicentre study in Asia [abstract]. Dig Dis Week 1998, 2:A-1.

    Google Scholar 

  46. Balzarini J, Wedgwoo O, Kruining J, et al.: Anti-HIV and anti-HBV activity and resistance profile of 3′-dideoxy-3′-thiacytidine (3TC) and its arylphosphoramidate derivative CF 1109. Biochem Biophys Res Commun 1996, 2:363–369.

    Article  Google Scholar 

  47. Bartholomew MM, Jansen RW, Jeffers LJ, et al.: Hepatitis-Bvirus resistance to lamivudine given for recurrent infection after orthotopic liver transplantation [comments]. Lancet 1997, 9044:20–22.

    Article  Google Scholar 

  48. Ling R, Mutimer D, Ahmed M, et al.: Selection of mutations in the hepatitis B virus polymerase during therapy of transplant recipients with lamivudine. Hepatology 1996, 3:711–713.

    Article  Google Scholar 

  49. Tipples GA, Ma MM, Fischer KP, et al.: Mutation in HBV RNAdependent DNA polymerase confers resistance to lamivudine in vivo. Hepatology 1996, 3:714–717.

    Google Scholar 

  50. Naoumov NV, Smith C, Williams R. Emergence and characterization of lamivudine resistant hepatitis B virus variant. Hepatology 1996, 24:282.

    Google Scholar 

  51. Schalm SW: Clinical implications of lamivudine resistance by HBV. Lancet 1997, 9044:3–4.

    Article  Google Scholar 

  52. Fischer KP, Tyrrell DLJ: Generation of duck hepatitis B virus polymerase mutants through site-directed mutagenesis which demonstrate resistance to lamivudine in vitro. Antimicrob Agents Chemother 1996, 40:1957–1960.

    PubMed  CAS  Google Scholar 

  53. Wainberg MA, Salomon H, Gu Z, et al.: Development of HIV-1 resistance to 29, 39-dideoxy-39-thiacytidine in patients with AIDS or advanced AIDS-related complex. AIDS 1995, 9:351–357.

    Article  PubMed  CAS  Google Scholar 

  54. Tisdale M, Kemp SD, Parry NR, et al.: Rapid in vitro selection of human immunodeficiency virus type 1 resistant to 3′-thiacytidine inhibitors due to a mutation in the YMDD region o reverse transcripture. Proc Natl Acad Sci U S A 1993, 90:5653–5656.

    Article  PubMed  CAS  Google Scholar 

  55. Allen MI, Deslauriers M, Andrews CW, et al.: Identification and characterization of mutation in hepatitis B virus resistant t lamivudine. Hepatology 1998, 27:1670–1677.

    Article  PubMed  CAS  Google Scholar 

  56. Aye TT, Bartholomeusz A, Shaw T, et al.: Hepatitis B virus polymerase mutations during antiviral therapy in a patient following liver transplantion. J Hepatol 1997, 26:1148–1153.

    Article  PubMed  CAS  Google Scholar 

  57. Tillman HL, Trantwein C, Krugor M, et al.: Inhibition of hepatitis B virus replication with lamivudine in patients previously treated with famciclovir after liver transplantation. J Hepatol 1997, 26 (suppl 1):153.

    Google Scholar 

  58. Lai CL, Liaw YF, Leung NMY, et al.: Genotype resistance to lamivudine in a prospective, placebo-controlled multicentre study in Asia of lamivudine therapy for chronic hepatitis B infection: incidence, kinetics of emergence and correlation with disease parameters [abstract]. Hepatology 1997, 26:259A.

    Google Scholar 

  59. Honkoop P, Niesters HG, de Man RA, et al.: Lamivudine resistance in immunocompetent chronic hepatitis B J Hepatol 1997, 26:1393–1395.

    Article  PubMed  CAS  Google Scholar 

  60. Chayama K, Suzuki Y, Kobayashi M, et al.: Emergence and takeover of YMDD motif mutant hepatitis B virus during longterm lamivudine therapy and re-takeover by wide type after cessation of therapy. Hepatology 1998, 27:1711–1716.

    Article  PubMed  CAS  Google Scholar 

  61. Melegari M, Scaglioni PP, Wands JR: Hepatitis B virus mutants associated with 3TC and famciclovir administration are replication defective. Hepatology 1998, 27:628–633.

    Article  PubMed  CAS  Google Scholar 

  62. Honkoop P, De Man RA, Scholte HR, et al.: Effect of lamivudine on morphology and function of mitochondria in patients with chronic hepatitis B. Hepatology 1997, 26:211–215.

    Article  PubMed  CAS  Google Scholar 

  63. Bain VE, Kneteman NM, Ma MM, et al.: Efficacy of lamivudine in chronic hepatitis B patients with active viral replication and decompensated cirrhosis undergoing liver transplantation. Transplantation 1996, 62:1456–1462.

    Article  PubMed  CAS  Google Scholar 

  64. Grellier L, Mutimer D, Ahmed M, et al.: Lamivudine prophylaxis against reinfection in liver transplantation for hepatitis B cirrhosis. Lancet 1996, 348:1212–1215.

    Article  PubMed  CAS  Google Scholar 

  65. Markowitz JS, Martin P, Conrad AJ, et al.: Prophylaxis against hepatitis B recurrence following liver transplantation using combination lamivudine and hepatitis B immune globulin. Hepatology in press.

  66. Yao F, Osorio R, Roberts J, et al.: Intramuscular hepatitis B immune globulin combined with oral lamivudine for prophylaxis against hepatitis B recurrence after liver transplantation [abstract]. Hepatology 1990, 28:261A.

    Google Scholar 

  67. Chan TM, Wu PC, Li FK, et al.: Treatment of fibrosing cholestatic hepatitis with lamivudine. Gastroenterology 1998, 115:177–181.

    Article  PubMed  CAS  Google Scholar 

  68. Cirelli R, Herne K, McCrary M, et al.: Famciclovir: review of clinical efficacy and safety. Antiviral Res 1996, 29:141–151.

    Article  PubMed  CAS  Google Scholar 

  69. Alrabiah FA, Sacks SL: New antiherpesvirus agents: their targets and therapeutic potential. Drugs 1996, 52:17–32.

    PubMed  CAS  Google Scholar 

  70. Korba BE, Boyd MR: Penciclovir is a selective inhibitor of hepatitis B virus replication in cultured human hepatoblastoma cells. Antimicrob Agents Chemother 1996, 40:1282–1284.

    PubMed  CAS  Google Scholar 

  71. Shaw T, Amor G, Civitico G, et al.: In vitro antiviral activity of penciclovir, a novel purine nucleoside, against duck hepatitis B virus. Antimicrob Agents Chemother 1994, 38:719–723.

    PubMed  CAS  Google Scholar 

  72. Lin E, Luscombe C, Wang YY, et al.: The guanine nucleoside analogue penciclovir is active against chronic duck hepatitis B virus infection in vivo. Antimicrob Agents Chemother 1996, 40:413–418.

    PubMed  CAS  Google Scholar 

  73. Shaw T, Mak SS, Locarnini SA: Inhibition of hepatitis B virus DNA polymerase by enantiomers of penciclovir triphosphate and metabolic basis for selective inhibition of HBV replication by penciclovir. Hepatology 1996, 24:996–1002.

    Article  PubMed  CAS  Google Scholar 

  74. Main J, Brown JL, Karayiannins P, et al.: A double-blind, placebo-controlled study to assess the affect of famciclovir on virus replication in patients with chronic hepatitis B virus infection. J Viral Hepatol 1996, 3:211–215.

    CAS  Google Scholar 

  75. Trepo C, Jezek P, Atkinson GF, et al.: Efficacy of famciclovir in chronic hepatitis B: results of a dose finding study [abstract]. Hepatology 1996, 24:419A.

    Article  Google Scholar 

  76. Goffin E, Horsmans Y, Pirson Y, et al.: Acute necrotic-hemorrhagic pancreatitis after famciclovir prescription. Transplantation 1995, 59:1218–1219.

    PubMed  CAS  Google Scholar 

  77. Singh N, Gayowski T, Wannstedt CF, et al.: Pretransplant famciclovir as prophylaxis for hepatitis B virus recurrence after liver transplantation. Transplantation 1997, 63:1415–1419.

    Article  PubMed  CAS  Google Scholar 

  78. Haller GW, Bechstein WO, Neuhaus R, et al.: Famiciclovir therapy for recurrent hepatitis B virus infection after liver transplantation. Transpl Int 1996, 9 (suppl 1):S210-S212.

    Article  PubMed  CAS  Google Scholar 

  79. Kruger M, Tillmann HL, Trautwein C, et al.: Famciclovir treatment of hepatitis B recurrence after liver tranplantation: pilot study. Liver Transpl Surg 1996, 2:253–262.

    Article  PubMed  CAS  Google Scholar 

  80. Prieto M, Cordoba J, Berenguer M, et al.: Famciclovir treatment of hepatitis B virus recurrence after orthotopic liver transplantation: a pilot study [abstract]. Hepatology 1995, 22:219A.

    Google Scholar 

  81. Boker KH, Ringe B, Kruger M, et al.: Prostaglandis E plus famciclovir: a new concept for the treatment of severe hepatitis B after liver transplantation. Transplantation 1994, 57:1706–1708.

    PubMed  CAS  Google Scholar 

  82. Rabinovits M, Dodson F, Rakela J: Famciclovir for recurrent hepatitis B (HBV) infection after liver transplantation [abstract]. Hepatology 1996, 24:282A.

    Google Scholar 

  83. Wolters LM, Honkoop P, Niesters HG, et al.: Efficacy of famciclovir treatment in chronic hepatitis B patients with different mutations at position 552 of the DNA polymerase gene. J Hepatol 1998, 28:909–910.

    Article  PubMed  CAS  Google Scholar 

  84. De Clercq E: Antiviral activity spectrum and target of action of different classes of nucleoside analogues. Nucleosides Nucleotides 1994, 13:1271–1295.

    Google Scholar 

  85. Gibson RJ, Chopra K, Murray-Lyon IM, et al.: A placebo-controlled phase I/II study of adefovir dipiroxil (bis-POM PMEA) in patients with chronic hepatitis B infection [abstract]. Hepatology 1996, 24(suppl 4):281A.

    Google Scholar 

  86. Jeffers L, Heathcote E, Wright T, et al.: A phase II dose-ranging, placebo-contolled trial of adefovir dipiroxil for the treatment of chronic hepatitis B virus infection [abstract]. Antiviral Res 1998, 37:A197.

    Google Scholar 

  87. Bloomer J, Chan R, Sherman M, et al.: A preliminary study of lobucavir for chronic hepatitis B [abstract]. Hepatology 1997, 26(suppl 4):428A.

    Google Scholar 

  88. Innaimo SF, Seifer M, Bisacchi GS, et al.: Identification of BMS-200475 as a potent and selective inhibitor of hepatitis B virus. Antimicrob Agents Chemother 1997, 41:1444–1448.

    PubMed  CAS  Google Scholar 

  89. Condreay LD, Condreay JP, Jansen RW, et al.: (-)cis-5-fluoro-1-[2-(hyfroxymethyl)-1,3-oxathiolan-5-y1] cytosine (524wal) inhibits hepatitis B virus replication in primary human hepatocytes. Antimicrob Agents Chemother 1996, 40:520–523.

    PubMed  CAS  Google Scholar 

  90. Dean J, Bowden S, Locarnini S: Reversal of duck hepatitis B virus DNA replication in vivo following cessation of treatment with the nucleoside analogue ganciclovir. Antiviral Res 1995, 27:171–178.

    Article  PubMed  CAS  Google Scholar 

  91. Civitico G, Wang YY, Luscombe C, et al.: Antiviral strategies in hepatitis B virus in vitro using conventional antiviral agents and supercoiled-DNA active compounds. J Med Virol 1990, 31:90–97.

    Article  PubMed  CAS  Google Scholar 

  92. Corey L, Holmes KK: Therapy for human immunodeficiency virus infection: what have we learned? N Engl J Med 1996, 335:1142–1144.

    Article  PubMed  CAS  Google Scholar 

  93. de Jonq MC, Boucher CAB, Galasso GJ, et al.: Consensus symposium on combined antiviral therapy. Antiviral Res 1995, 29:5–29.

    Google Scholar 

  94. Colledge D, Locarnini S, Shaw T: Synergistic inhibition of hepadnaviral replication by lamivudine in combination with penciclovir in vitro. Hepatology 1997, 26:216–225.

    PubMed  CAS  Google Scholar 

  95. Fontana R, Lok ASF: Combination therapy for chronic hepatitis B. Hepatology 1997, 26:234–237.

    Article  PubMed  CAS  Google Scholar 

  96. Shaw T, Colledge D, Locarnini SA: Synergistic inhibition of in vitro hepadnaviral replication by PMEA and penciclovir or lamivudine [abstract]. Antiviral Res 1997, 34:A33.

    Article  Google Scholar 

  97. Xiong X, Gibbs C, Toole J: Lack of cross resistance to PMEA for human HBV polymerases which express lamivudine resistance codons [abstract]. Hepatology 1997, 26(4suppl):431A.

    Google Scholar 

  98. Heathcote J: Lamivudine and intron A combination treatment in patients with chronic hepatitis B infection [abstract]. J Hepatol 1998, 28(1suppl):43.

    Article  Google Scholar 

  99. Perrillo RP: Interferon in the management of chronic hepatitis B. Dig Dis Sci 1993, 38:577–593.

    Article  PubMed  CAS  Google Scholar 

  100. Kruger M, Boker KH, Zeidler H, et al.: Treatment of hepatitis Brelated polyarthritis nodosa with famciclovir and interferon alfa-2b. J Hepatol 1997, 26:935–939.

    Article  PubMed  CAS  Google Scholar 

  101. Hinrichsen H, Vollmar J, Barnass S, et al.: Combination therapy of chronic hepatitis B with a-interferon and famciclovir: a report of 2 cases [abstract]. Hepatology 1997, 26(suppl 4):524A.

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. California Pacific Medical Center, 2340 Clay Street, Suite #251, 94115, San Francisco, CA, USA

    Francis Yao MD & Robert G. Gish MD

Authors
  1. Francis Yao MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Robert G. Gish MD
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Yao, F., Gish, R.G. Treatment of chronic hepatitis B: New antiviral therapies. Curr Gastroenterol Rep 1, 20–26 (1999). https://doi.org/10.1007/s11894-999-0082-7

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11894-999-0082-7

Keywords

Search

Navigation